Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood- based test in breast cancer

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Radpour, Ramin ^a   Barekati, Zeinab ^a   Kohler, Corina ^a   Lv, Qing ^b   Bürki, Nicole ^c   Diesch, Claude ^c   Bitzer, Johannes ^a   Zheng, Hong ^b   Schmid, Seraina ^a   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SICHUAN UNIVERSITY   (China)

^c Kantonsspital ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; APC GENE; ARTICLE; BIN1 GENE; BLOOD EXAMINATION; BLOOD SAMPLING; BMP6 GENE; BREAST CANCER; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; CST6 GENE; DNA METHYLATION; ESR B GENE; FEMALE; GSTP1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; P16 GENE; P21 GENE; SENSITIVITY AND SPECIFICITY; TIMP3 GENE; TUMOR SUPPRESSOR GENE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; CPG ISLAND; GENE REGULATORY NETWORK; GENETICS; TUMOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE REGULATORY NETWORKS; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 79551513940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016080     Document Type: Article

References (35)

1. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243-252.
2. Ries L MD, Krapcho M, Mariotto A, Miller B, Feuer E (2006) SEER cancer statistics review, 1975-2004. Bethesda: National Cancer Institute.
3. Radpour R, Barekati Z, Kohler C, Holzgreve W, Zhong XY (2009) New trends in molecular biomarker discovery for breast cancer. Genet Test Mol Biomarkers 13: 565-571.
4. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650.
5. Chan KC, Zhang J, Hui AB, Wong N, Lau TK, et al. (2004) Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 50: 88-92.
6. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, et al. (2004) Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157-4164.
7. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, et al. (1998) Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17: 89-97.
8. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, et al. (2007) Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 276: 327-331.
9. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
10. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, et al. (2004) Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64: 4442-4452.
11. Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482.
12. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683-692.
13. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, et al. (2004) Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 10: 2401-2406.
14. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, et al. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 102: 15785-15790.
15. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, et al. (2008) Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci U S A 105: 4844-4849.
16. Radpour R, Haghighi MM, Fan AX, Torbati PM, Hahn S, et al. (2008) High- Throughput Hacking of the Methylation Patterns in Breast Cancer by In vitro Transcription and Thymidine-Specific Cleavage Mass Array on MALDI-TOF Silico-Chip. Mol Cancer Res 6: 1702-1709.
17. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, et al. (2009) Methylation profiles of 22 candidate genes in breast cancer using highthroughput MALDI-TOF mass array. Oncogene 28: 2969-2978.
18. Radpour R, Sikora M, Grussenmeyer T, Kohler C, Barekati Z, et al. (2009) Simultaneous Isolation of DNA, RNA, and Proteins for Genetic, Epigenetic, Transcriptomic, and Proteomic Analysis. J Proteome Res 8: 5264-5274.
19. Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, et al. (2010) Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Hum Mol Genet 19: 2936-2946.
20. Radpour R, Barekati Z, Haghighi MM, Kohler C, Asadollahi R, et al. (2010) Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 23: 763-772.
21. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, et al. (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38: 1378-1385.
22. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, et al. (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665.
23. Diehl F, Li M, Dressman D, He Y, Shen D, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102: 16368-16373.
24. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
25. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, et al. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645.
26. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10: 6189-6193.
27. Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, et al. (2006) Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 1: 88-93.
28. Sunami E VA-T, Nguyen SL, Hoon DSB (2009) Analysis of methylated circulating DNA in cancer patients' blood DNA Methylation. pp 349-356.
29. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, et al. (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10: 5349-5354.
30. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, et al. (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107: 970-975.
31. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, et al. (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11: 2156-2162.
32. Tao MH, Shields PG, Nie J, Millen A, Ambrosone CB, et al. (2009) DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 114: 559-568.
33. Li S, Rong M, Iacopetta B (2006) DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237: 272-280.
34. Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476.
35. Li Y, Zimmermann B, Rusterholz C, Kang A, Holzgreve W, et al. (2004) Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem 50: 1002-1011.